Cara Therapeutics downgraded by Canaccord Genuity with a new price target
$CARA
Biotechnology: Pharmaceutical Preparations
Health Care
Canaccord Genuity downgraded Cara Therapeutics from Buy to Hold and set a new price target of $1.00 from $10.00 previously